Both of these drugs are once weekly GLP-1 analogues used in the treatment of type 2 diabetes
In contrast, evidence from neuroimaging remains limited
In certain clinical trials, when compared to a placebo, patients who used Wegovy lost about 15% of their starting body weight in the first 1 to 1.5 years, Zepbound medication users lost 16%, Foundayo medication users lost 12.4%, and Saxenda users lost 5%
57.5%), while males experienced early-phase events ( 30 days
An inability of the GT II assay to identify the genotype 1 subtype may be due to (i) the presence of genetic variability in the NS5B region in which the probes specific for subtype 1a or 1b detection anneal (majority in the present study), (ii) the presence of rare HCV-1 subtypes (four cases observed), or (iii) the presence of certain genotype 6 subtypes in which the 5NC region targeted by the genotype 1-specific probe is identical to some 1b subtypes 11,13,33 (none observed in our study)
Please discuss your specific concern at consultation and we will advise on the most appropriate approach